ResearchPublications

HUTOX® Inj. is an injectable product containing Botulinum Toxin Type A, manufactured by Huons BioPharma Co., Ltd., a South Korean bio technology company. Similar to other Botulinum Toxin Type A products, HUTOX® Inj. is used for both medical and cosmetic purposes by temporarily relaxing targeted muscles.

1. Anatomical injection guidelines for glabellar frown lines based on ultrasonographic evaluation. Toxins (2021)

2. Efficacy and safety of a new botulinum toxin (HU-014) versus existing onabotulinumtoxin A in subjects with moderate to severe glabellar lines. Dermatologic Surgery (2021)

3. Phase I/III clinical trial to evaluate the safety and efficacy of a new botulinum toxin (HU-014) versus OnabotulinumtoxinA in subjects with moderate-to-severe crow's feet lines. Dermatologic Surgery (2021)

4. An update on the cosmetic use of botulinum toxin: the pattern of practice among Korean dermatologists. Toxins (2022)

5. Safety and Efficacy of HU-014 in the Treatment of Post-Stroke Upper Limb Spasticity: A Phase I Pilot Study. Toxins (2022)

6. Ultrasonographic analyses of crow's feet and novel guideline for botulinum toxin injection. Journal of Cosmetic Dermatology (2022)

7. A Randomized, Double-Blind, Active Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Liztox® versus Botox® in Post-Stroke Upper Limb Spasticity. Toxins (2023)

8. Is There a Correlation Between Masticatory Muscle Thickness and Pain After Botulinum Toxin Injections in Myogenic TMD Patients?: A Pilot Study. Toxins (2025)